Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies (Q33964193)

30 July 2017

1 reference

title

Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies (English)

1 reference

30 July 2017

1 reference

Dal Piaz V

1

1 reference

PubMed ID

10889326

30 July 2017

Giovannoni MP

series ordinal

2

1 reference

30 July 2017

1 May 2000

1 reference

European Journal of Medicinal Chemistry

30 July 2017

1 reference

30 July 2017

35

1 reference

30 July 2017

5

1 reference

30 July 2017

463-480

1 reference

Expression and regulation of human and rat phosphodiesterase type IV isogenes

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Stereospecific binding of the antidepressant rolipram to brain protein structures

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. III. N-cyclohexyl-N-(2-hydroxyethyl)-4-(1,2-dihydro-2-oxo-6-quinolyloxy)-butyramide and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Enoximone. A review of its pharmacological properties and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Selective inhibition of one of the cyclic AMP phosphodiesterases from rat brain by the neurotropic compound rolipram.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Recent advances in pulmonary medicine (1).

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Morphology of the airway wall in asthma and in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Airway mucosal inflammation even in patients with newly diagnosed asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

1 reference

7 January 2021

Clinical pharmacology of corticosteroids in bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Regular inhaled beta-agonist treatment in bronchial asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Questions about inhaled beta 2-adrenoceptor agonists in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

COPD: new developments and therapeutic opportunities.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Inhibition of lipopolysaccharide-induced bowel erythrocyte extravasation in rats, and of mesenteric hypoperfusion in dogs, by phosphodiesterase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

The clinical use of beta-receptor agonists: for and against

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Clinical pharmacology of asthma. Implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Aminophylline toxicity--how many hospital asthma deaths does it cause?

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Theophylline in the management of asthma: time for reappraisal?

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Need for theophylline in severe steroid-requiring asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Inflammatory mechanisms and nocturnal asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Effects of enprofylline and theophylline may show the role of adenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Intravenous salbutamol and aminophylline in asthma: a search for synergy

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Specific antagonism of adenosine-induced bronchoconstriction in asthma by oral theophylline

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Relationships between adenosine, cyclic nucleotides, and xanthines in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Mechanism for the emetic side effect of xanthine bronchodilators

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Pentoxifylline prevents tumor necrosis factor-induced lung injury

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

TVX 2706 — a new phosphodiesterase inhibitor with antiinflammatory action Biochemical characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Substituted 1,8-naphthyridin-2(1H)-ones as selective phosphodiesterase IV inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Prenatal glucocorticoid and T4 effects on lung morphology in preterm lambs

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Nicotinamide ethers: novel inhibitors of calcium-independent phosphodiesterase and [3H]rolipram binding

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Selective tracheal relaxation and phosphodiesterase-IV inhibition by xanthine derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Bronchodilator activity of xanthine derivatives substituted with functional groups at the 1- or 7-position

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Effects of alkyl substitutions of xanthine skeleton on bronchodilation

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Selective bronchodilators from 1-(5'-oxohexyl)xanthines

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Bovine cone photoreceptor cGMP phosphodiesterase structure deduced from a cDNA clone

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

The presence of five cyclic nucleotide phosphodiesterase isoenzyme activities in bovine tracheal smooth muscle and the functional effects of selective inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

PDE4 inhibitors: new xanthine analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Effect of ibudilast: a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

New imidazo(1,2-a)pyrazine derivatives with bronchodilatory and cyclic nucleotide phosphodiesterase inhibitory activities

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Antibronchoconstrictor activity of two new phosphodiesterase inhibitors, a triazolopyrazine (ICI 58 301) and a triazolopyrimidine (ICI 63 197).

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Benzofuran based PDE4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

Phosphodiesterase 4 inhibitors as airways smooth muscle relaxant agents: synthesis and biological activities of triazine derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900179-3

7 January 2021

10.1016/S0223-5234(00)00179-3

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10889326